Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure
A Phase 1/2 Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination With Bevacizumab for Adult Patients With Recurrent Malignant Glioma Post-Bevacizumab Failure
The primary objectives of the study are to determine the maximum tolerated dose (MTD) of Carboxyamidotriazole Orotate (CTO) when combined with standard dosing of bevacizumab among patients with recurrent malignant glioma (WHO grade III or IV) that have previously failed bevacizumab (Phase 1); to determine the activity of CTO alone in bevacizumab-failure WHO grade IV malignant glioma patients (Phase 2, Arm 1); to determine the activity of CTO plus bevacizumab in bevacizumab-failure WHO grade IV malignant glioma patients (Phase 2, Arm 2).
This study was terminated early due to funding issues. At the time of termination, the study was still in Phase 1 and no MTD for the combination of CTO and bevacizumab had been determined for this population. Phase 2 will not proceed.
研究概览
详细说明
In Phase 1 of the study, we will conduct a dose-escalation study of the combination of CTO with the standard dosing of bevacizumab among patients with recurrent malignant glioma (WHO Grade III or IV) that have previously failed bevacizumab. All patients will have also received standard treatment with radiation therapy and temozolomide prior to enrollment on study.
The Phase 2 portion of this study will investigate two novel treatment regimens sequentially. Each regimen will include 25 patients with recurrent WHO grade IV malignant glioma who have been treated in the past with standard radiation therapy, temozolomide, and bevacizumab. All patients must have failed therapy while on bevacizumab. Subjects in the first treatment regimen will receive CTO alone and subjects in the second treatment regimen will receive the combination of CTO and bevacizumab together.
Note: This study was terminated early due to funding issues. At the time of termination, the study was still in Phase 1 and no MTD for the combination of CTO and bevacizumab had been determined for this population. Phase 2 will not proceed.
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
North Carolina
-
Durham、North Carolina、美国、27710
- The Preston Robert Tisch Brain Tumor Center at Duke
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Phase 1 portion: Patients must have recurrent histologically confirmed diagnosis of World Health Organization (WHO) grade III or IV malignant glioma with no more than 3 prior progressions
- Phase 2 portion: Patients must have recurrent histologically confirmed diagnosis of WHO grade IV malignant glioma (glioblastoma or gliosarcoma) with no more than 3 prior progressions.
- Must have had a least 1 prior progression on a bevacizumab-containing regimen
- Age greater than or equal to 18 years
- Karnofsky ≥ 70%
- Bi-dimensionally measurable disease, as assessed by magnetic resonance imaging based on The Revised Assessment in Neuro-Oncology (RANO) criteria
- Absolute neutrophil count (ANC) ≥1000 cells/µl, Platelets ≥ 100,000 cells/µl (without transfusion within 14 days before enrollment)
- Adequate renal function as indicated by the following: Serum creatinine < 1.25 times upper limit of normal (ULN) or calculated creatinine clearance ≥ 50 ml/min; Urine dipstick for proteinuria < 2+ unless a 24-hour urine protein <1 g of protein is demonstrated
- Prothrombin time (PT) ≤ 1.5 x ULN and activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN within 14 days prior to first study treatment for patients not receiving anti-coagulation. The use of full-dose oral or parenteral anticoagulants is permitted as long as the PT or aPTT is within therapeutic limits (according to the medical standard of the enrolling institution) and the patient has been on a stable dose of anticoagulants for at least two weeks prior to the first study treatment.
- For patients on corticosteroids, they must be on a stable dose for 7 days prior to anticipated start of study drug, and the dose should not be escalated over entry dose level, if clinically possible
- Signed informed consent approved by the Institutional Review Board
- No evidence of > grade 1 active central nervous system (CNS) hemorrhage on the baseline magnetic resonance imaging (MRI) or computed tomography (CT) scan
- Female patients must not be pregnant or breast-feeding. Female patients of childbearing potential (defined as < 2 years after last menstruation or not surgically sterile) must use a highly effective contraceptive method (allowed methods of birth control, [i.e. with a failure rate of < 1% per year] are implants, injectables, combined oral contraceptives, intra-uterine device (IUD) (only hormonal), sexual abstinence or vasectomized partner) during the trial and for a period of > 6 months following the last administration of trial drug(s). Female patients with an intact uterus (unless amenorrhea for the last 24 months) must have a negative serum pregnancy test within 48 hours prior to first study treatment.
- Fertile male patients must agree to use a highly effective contraceptive method (allowed methods of birth control [i.e. with a failure rate of < 1% per year] include a female partner using implants, injectables, combined oral contraceptives, IUDs [only hormonal], sexual abstinence or prior vasectomy) during the trial and for a period of > 6 months following the last administration of trial drugs.
Exclusion Criteria:
- Pregnancy or breast-feeding
- Co-medication that may interfere with study results, for example, immuno-suppressive agents other than corticosteroids
- Active infection requiring intravenous (IV) antibiotics within 7 days before enrollment
- Prior, unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin
- Taking cytochrome P450 3A4 (CYP3A4) inducers and moderate or strong inhibitors (Note: Corticosteroids are allowed, as long as patients have been on a stable dose for 7 days prior to anticipated start of study drug, and the dose should not be escalated over entry dose level, if clinically possible)
- Less than 12 weeks from radiation therapy, unless progressive disease outside of the radiation field or progression on 2 consecutive scans or histopathologic confirmation
- Treated with immunotherapeutic agents or vaccines within 4 weeks before enrollment, unless the patient has recovered from the expected toxic effects of such therapy
- Treated with alkylating agents within 4 weeks before enrollment or treated with daily or metronomic chemotherapy within 1 week before enrollment, unless the patient has recovered from the expected toxic effects of such therapy
- Prior chemotherapy (non-alkylating agents) within 2 weeks before enrollment, unless the patient has recovered from the expected toxic effects of such therapy
- Current, recent (within 4 weeks of the first infusion of this study) use of an experimental drug, unless the patient has recovered from the expected toxic effects of study therapy
Vascular endothelial growth factor (VEGF) Inhibitor-Specific Exclusion Criteria are:
- Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg) within 28 days of first study treatment
- Prior history of hypertensive crisis, hypertensive encephalopathy, reverse posterior leukoencephalopathy syndrome (RPLS)
- Prior history of gastrointestinal perforation or abscess
- Clinically significant (active) cardiovascular disease, for example cerebrovascular accidents ≤ 6 months prior to study enrollment, myocardial infarction ≤ 6 months prior to study enrollment, unstable angina, New York Heart Association (NYHA) Grade 2 or greater congestive heart failure (CHF), or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with protocol treatment
- History or evidence upon physical/neurological examination of central nervous system disease (for example, seizures) unrelated to cancer unless adequately controlled by medication or potentially interfering with protocol treatment
- Significant vascular disease (for example, aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to start of study treatment
- History of pulmonary hemorrhage/hemoptysis ≥ grade 2 (defined as ≥ 2.5 mL bright red blood per episode) within 1 month of first study treatment
- History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (in the absence of therapeutic anticoagulation)
- Current or recent (within 10 days of study enrollment) use of aspirin (> 325 mg/day), clopidogrel (> 75 mg/day) or equivalent. Prophylactic or therapeutic low molecular weight heparin (LMWH) is allowed.
- Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to first study treatment, or anticipation of need for major surgical procedure during the course of the study
- Minor surgical procedure, for example, stereotactic biopsy, within 7 days of first study treatment; placement of a vascular access device, within 2 days of first study treatment
- History of intracranial abscess within 6 months prior to first study treatment
- History of active gastrointestinal bleeding within 6 months prior to first study treatment
- Serious, non-healing wound, active ulcer, or untreated bone fracture
- Known hypersensitivity to any component of bevacizumab or CTO
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:CTO and Bevacizumab (Phase 1)
The combination of CTO with the standard dosing of bevacizumab of 10 mg/kg every 2 weeks among patients with recurrent malignant glioma (World Health Organization (WHO) grade III or IV) that have previously failed bevacizumab
|
其他名称:
|
实验性的:Phase 2: CTO alone (Phase 2)
The first 25 patients will be treated with CTO alone at the maximum tolerated dose (MTD) established in the Phase 1 portion of the study.
|
其他名称:
|
实验性的:CTO and Bevacizumab (Phase 2)
The second group of 25 patients will be treated with the combination of CTO at the MTD established in the Phase 1 portion of this study and standard dosing of bevacizumab.
|
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Phase 1: Determine the Maximum Tolerated Dose (MTD) of CTO when combined with standard dosing of bevacizumab
大体时间:1 year
|
A standard "3+3" design to determine the MTD of CTO in combination with bevacizumab.
Subjects will be administered CTO orally on a continuous daily dosing schedule, while subjects will receive bevacizumab (10 mg/kg) every 2 weeks.
Cohorts of 3-6 subjects will accrue at each dose level of CTO, beginning with 225 mg/m2, until MTD is defined.
The MTD is the highest dose level at which ≤ 1 out of 6 experienced a dose limiting toxicity (DLT).
|
1 year
|
Phase 2: Percentage of subjects who remain alive and progression-free at 6 months
大体时间:2 years
|
Percentage of participants surviving six months from start of study treatment without progression of disease.
Progression-free survival (PFS) was defined as the time from start of study treatment to the date of the first documented progression according to the Response Assessment in Neuro-Oncology (RANO) criteria, or to death due to any cause.
|
2 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
第 2 阶段:在任何方案治疗周期期间经历剂量限制性毒性 (DLT) 的受试者百分比
大体时间:2年
|
将使用不良事件通用术语标准 (CTCAE) 4.0 版收集所有毒性。 DLT 将被定义为以下任何可能、可能或肯定归因于 CTO 或洛莫司汀的事件: 非血液学:
血液学:
|
2年
|
Phase 1: Number of subjects who experience a dose-limiting toxicity (DLT) during cycle 1
大体时间:1 year
|
All toxicities will be collected using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. DLTs will be defined as any of the following events that are possibly, probably, or definitely attributable to CTO or lomustine: Non-hematologic:
Hematologic:
|
1 year
|
Phase 2: Median Overall Survival (OS)
大体时间:2 years
|
Time in months from start of study treatment to date of death due to any cause.
Patients alive as of the last follow-up will have OS censored at the last follow-up date.
Median OS will be estimated using a Kaplan-Meier curve.
|
2 years
|
Phase 2: 6 and 12 month Overall Survival (OS)
大体时间:2 years
|
Percentage of participants surviving 6 and 12 months from start of study treatment.
OS is defined as time from start of study treatment to the date of death due to any cause.
|
2 years
|
Phase 2: Percentage of subjects with best overall response (BOR) of complete response (CR) or partial response (PR)
大体时间:2 years
|
Response is based on Response Assessment in Neuro-Oncology (RANO) criteria as determined by investigator assessment.
A confirmation of response was not required.
Complete Response was defined as complete disappearance on MR/CT of all enhancing tumor and mass effect, off all corticosteroids (or receiving only adrenal replacement doses), accompanied by a stable or improving neurologic examination, and maintained for at least 4 weeks.
Partial Response was defined as greater than or equal to 50% reduction in tumor size on MR/CT by bi-dimensional measurement, on a stable or decreasing dose of corticosteroids, accompanied by a stable or improving neurologic examination, and maintained for at least 4 weeks.
|
2 years
|
Phase 2: Median PFS
大体时间:2 years
|
Time in months from start of study treatment to the date of first progression according to RANO criteria, or to death due to any cause.
Patients alive who had not progressed as of the last follow-up will have PFS censored at the last follow-up date.
Median PFS will be estimated using a Kaplan-Meier curve.
|
2 years
|
Phase 2: 12 month PFS
大体时间:2 years
|
Percentage of participants surviving six months from the start of study treatment without progression of disease.
PFS is defined as the time from the date of study treatment initiation to the date of the first documented progression according to the RANO criteria, or to death due to any cause.
|
2 years
|
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
恶性神经胶质瘤(WHO III 级或 IV 级)的临床试验
-
University of GöttingenHannover Medical School; Deutsche Kinderkrebsstiftung招聘中弥漫性脑桥脑胶质瘤 | 脑胶质瘤病 | 胶质母细胞瘤 WHO IV 级 | 弥漫性中线胶质瘤组蛋白 3 K27M WHO IV 级 | 间变性星形细胞瘤 WHO III 级德国
-
Children's Hospital Medical Center, Cincinnati终止
-
Michael Vogelbaum, MD, PhDInfuseon Therapeutics, Inc.完全的
-
Annick DesjardinsTactical Therapeutics, Inc.终止
-
Artiva Biotherapeutics, Inc.招聘中
-
Beijing Tiantan HospitalZhongSheng BioTech Inc.招聘中
-
Kyverna Therapeutics招聘中狼疮性肾炎 | 狼疮性肾炎 - WHO IV 级 | 狼疮性肾炎 - WHO III 级德国
-
Rigel PharmaceuticalsNationwide Children's Hospital尚未招聘星形细胞瘤 | 高级别胶质瘤 | 少突神经胶质瘤 | 弥漫性脑桥脑胶质瘤 | 弥漫性中线胶质瘤,H3 K27M 突变体 | WHO III 级神经胶质瘤 | 转移性脑肿瘤 | 脊柱肿瘤 | 星形细胞瘤,III 级 | 星形细胞瘤,IV 级 | IDH1突变 | WHO IV级神经胶质瘤 | 丘脑肿瘤 | IDH1 R132 | IDH1 R132C | IDH1 R132H | IDH1 R132S | IDH1 R132G | IDH1 R132L美国, 澳大利亚, 英国, 加拿大, 德国, 荷兰
-
Kyverna Therapeutics招聘中狼疮性肾炎 | 狼疮性肾炎 - 世界卫生组织 (WHO) III 级 | 狼疮性肾炎 - WHO IV 级美国
-
Nationwide Children's HospitalPfizer尚未招聘胶质母细胞瘤 | 多形性胶质母细胞瘤 | 高级别胶质瘤 | 间变性星形细胞瘤 | 弥漫性脑桥脑胶质瘤 | WHO III 级神经胶质瘤 | WHO IV级神经胶质瘤 | 婴儿型半球胶质瘤 | 弥漫性中线胶质瘤,H3K27 改变美国, 澳大利亚, 加拿大, 德国, 荷兰
CTO and Bevacizumab的临床试验
-
National Institute of Cardiology, Warsaw, Poland招聘中
-
Universitätsmedizin MannheimIHF GmbH - Institut für Herzinfarktforschung; Herzzentrum Lahr尚未招聘冠状动脉疾病 | 心脏衰竭 | 慢性完全闭塞
-
Kerckhoff Heart CenterInstitute of Cardiology, Warsaw, Poland; University of Giessen; University Hospital Erlangen完全的
-
Yale UniversityBoston Scientific Corporation终止
-
AngioSafe, Inc.Veranex, Inc.招聘中
-
National Institute of Cardiology, Warsaw, Poland招聘中
-
Belfast Health and Social Care TrustBristol Royal Infirmary; Royal Infirmary of Edinburgh; Golden Jubilee National Hospital未知